Literature DB >> 17061959

Warfarin: almost 60 years old and still causing problems.

Munir Pirmohamed1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17061959      PMCID： PMC1885167          DOI： 10.1111/j.1365-2125.2006.02806.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  20 in total

1.  Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study.

Authors:  G McGwin; R V Sims; L Pulley; J M Roseman
Journal:  Am J Epidemiol       Date:  2000-09-01       Impact factor: 4.897

2.  Efficient operation of a high-volume anticoagulation clinic.

Authors:  M T Foss; P H Schoch; C D Sintek
Journal:  Am J Health Syst Pharm       Date:  1999-03-01       Impact factor: 2.637

3.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  The safety and effectiveness of a nurse-led anticoagulant service.

Authors:  Carole A Connor; Chris C Wright; Christopher D Fegan
Journal:  J Adv Nurs       Date:  2002-05       Impact factor: 3.187

5.  Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy.

Authors:  R F Ellis; M A Stephens; G B Sharp
Journal:  Am J Hosp Pharm       Date:  1992-02

Review 6.  Pharmacogenetics of warfarin: current status and future challenges.

Authors:  M Wadelius; M Pirmohamed
Journal:  Pharmacogenomics J       Date:  2006-09-19       Impact factor: 3.550

7.  Evaluation of warfarin dosing by pharmacists for elderly medical in-patients.

Authors:  Naomi Burns
Journal:  Pharm World Sci       Date:  2004-08

8.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03

9.  Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK.

Authors:  S Stewart; N F Murphy; N Murphy; A Walker; A McGuire; J J V McMurray
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

10.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Authors:  Lori-Ann Linkins; Peter T Choi; James D Douketis
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391
View more
  67 in total

1.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

2.  Checklists for the use of novel oral anticoagulants by the front-line clinician.

Authors:  Tammy J Bungard; Jennifer Bolt; Peter Thomson; William Semchuk; Jennifer Lowerison
Journal:  Can Pharm J (Ott)       Date:  2015-09

3.  Development of oral anticoagulants.

Authors:  Qing Ma
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

4.  Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method.

Authors:  Hussain A Isma'eel; George E Sakr; Robert H Habib; Mohamad Musbah Almedawar; Nathalie K Zgheib; Imad H Elhajj
Journal:  Eur J Clin Pharmacol       Date:  2013-12-03       Impact factor: 2.953

5.  Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.

Authors:  Faiza Yasmeen; Muhammad Bilal Ghafoor; Abdul Wadood Khalid; Waqas Latif; Shahida Mohsin; Shagufta Khaliq
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

6.  LC-MS-MS Analysis of Brodifacoum Isomers in Rat Tissue.

Authors:  Zane Z Hauck; Douglas L Feinstein; Richard B van Breemen
Journal:  J Anal Toxicol       Date:  2016-02-23       Impact factor: 3.367

7.  Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes.

Authors:  Laura G Stoudenmire; Christina E DeRemer; Hazem Elewa
Journal:  Int J Hematol       Date:  2014-06-21       Impact factor: 2.490

8.  Multivariate analysis of the relation between diet and warfarin dose.

Authors:  Morten Arendt Rasmussen; Jane Skov; Else-Marie Bladbjerg; Johannes J Sidelmann; Marianne Vamosi; Jørgen Jespersen
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

9.  New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting.

Authors:  Jacob K Hilton; Wade D Van Horn
Journal:  Nat Struct Mol Biol       Date:  2017-01-05       Impact factor: 15.369

10.  Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital.

Authors:  Subramaniam Thanimalai; Asrul Akmal Shafie; Mohamed Azmi Hassali; Jeyaindran Sinnadurai
Journal:  Int J Clin Pharm       Date:  2013-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.